TOT BIOPHARM International (HKG:1875) reported a net profit attributable to the equity holders of 35.4 million yuan for the nine months ended Sept. 30, compared with a loss of 32.4 million yuan in the corresponding period of the previous year, according to a Tuesday filing with the Hong Kong Stock Exchange.
The company's revenue was 809.0 million yuan, compared with 542.0 million yuan in the previous year period.
The company's shares were down about 6% in the recent trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。